These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

466 related articles for article (PubMed ID: 11336691)

  • 1. Type i interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo.
    Le Bon A; Schiavoni G; D'Agostino G; Gresser I; Belardelli F; Tough DF
    Immunity; 2001 Apr; 14(4):461-70. PubMed ID: 11336691
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Slc15a4 function is required for intact class switch recombination to IgG2c in response to TLR9 stimulation.
    Dosenovic P; Ádori M; Adams WC; Pedersen GK; Soldemo M; Beutler B; Karlsson Hedestam GB
    Immunol Cell Biol; 2015 Feb; 93(2):136-46. PubMed ID: 25310967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Type I interferon as a powerful adjuvant for monocyte-derived dendritic cell development and activity in vitro and in Hu-PBL-SCID mice.
    Santini SM; Lapenta C; Logozzi M; Parlato S; Spada M; Di Pucchio T; Belardelli F
    J Exp Med; 2000 May; 191(10):1777-88. PubMed ID: 10811870
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Links between innate and adaptive immunity via type I interferon.
    Le Bon A; Tough DF
    Curr Opin Immunol; 2002 Aug; 14(4):432-6. PubMed ID: 12088676
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant activity of type I interferons.
    Tovey MG; Lallemand C; Thyphronitis G
    Biol Chem; 2008 May; 389(5):541-5. PubMed ID: 18953720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Type I IFN as a vaccine adjuvant for both systemic and mucosal vaccination against influenza virus.
    Bracci L; Canini I; Venditti M; Spada M; Puzelli S; Donatelli I; Belardelli F; Proietti E
    Vaccine; 2006 Apr; 24 Suppl 2():S2-56-7. PubMed ID: 16823927
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The adjuvant effects of the toll-like receptor 3 ligand polyinosinic-cytidylic acid poly (I:C) on antigen-specific CD8+ T cell responses are partially dependent on NK cells with the induction of a beneficial cytokine milieu.
    Salem ML; El-Naggar SA; Kadima A; Gillanders WE; Cole DJ
    Vaccine; 2006 Jun; 24(24):5119-32. PubMed ID: 16704888
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Type I IFN enhances follicular B cell contribution to the T cell-independent antibody response.
    Swanson CL; Wilson TJ; Strauch P; Colonna M; Pelanda R; Torres RM
    J Exp Med; 2010 Jul; 207(7):1485-500. PubMed ID: 20566717
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Poly(gamma-glutamic acid) nanoparticles as an efficient antigen delivery and adjuvant system: potential for an AIDS vaccine.
    Wang X; Uto T; Akagi T; Akashi M; Baba M
    J Med Virol; 2008 Jan; 80(1):11-9. PubMed ID: 18041033
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Direct effect of dsRNA mimetics on cancer cells induces endogenous IFN-β production capable of improving dendritic cell function.
    Gatti G; Nuñez NG; Nocera DA; Dejager L; Libert C; Giraudo C; Maccioni M
    Eur J Immunol; 2013 Jul; 43(7):1849-61. PubMed ID: 23636788
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant regulation of cytokine profile and antibody isotype of immune responses to Mycoplasma agalactiae in mice.
    Avramidis N; Victoratos P; Yiangou M; Hadjipetrou-Kourounakis L
    Vet Microbiol; 2002 Sep; 88(4):325-38. PubMed ID: 12220808
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cutting edge: enhancement of antibody responses through direct stimulation of B and T cells by type I IFN.
    Le Bon A; Thompson C; Kamphuis E; Durand V; Rossmann C; Kalinke U; Tough DF
    J Immunol; 2006 Feb; 176(4):2074-8. PubMed ID: 16455962
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo and in vitro regulation of type I IFN synthesis by synergistic effects of CD40 and type II IFN.
    Greene JA; DeVecchio JL; Gould MP; Auletta JJ; Heinzel FP
    J Immunol; 2006 May; 176(10):5995-6003. PubMed ID: 16670308
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CpG DNA induces IgG class switch DNA recombination by activating human B cells through an innate pathway that requires TLR9 and cooperates with IL-10.
    He B; Qiao X; Cerutti A
    J Immunol; 2004 Oct; 173(7):4479-91. PubMed ID: 15383579
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulation of cytokine gene expression by adjuvants in vivo.
    Victoratos P; Yiangou M; Avramidis N; Hadjipetrou L
    Clin Exp Immunol; 1997 Sep; 109(3):569-78. PubMed ID: 9328138
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liposome-encapsulated CpG oligodeoxynucleotides as a potent adjuvant for inducing type 1 innate immunity.
    Suzuki Y; Wakita D; Chamoto K; Narita Y; Tsuji T; Takeshima T; Gyobu H; Kawarada Y; Kondo S; Akira S; Katoh H; Ikeda H; Nishimura T
    Cancer Res; 2004 Dec; 64(23):8754-60. PubMed ID: 15574787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modulation of Innate Immunity by lignin-Carbohydrate, a Novel TLR4 Ligand, Results in Augmentation of Mucosal IgA and Systemic IgG Production.
    Tsuji R; Ikado K; Fujiwara D
    Int J Mol Sci; 2017 Dec; 19(1):. PubMed ID: 29278400
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulation by interferon alpha of immunoglobulin isotype selection and lymphokine production in mice.
    Finkelman FD; Svetic A; Gresser I; Snapper C; Holmes J; Trotta PP; Katona IM; Gause WC
    J Exp Med; 1991 Nov; 174(5):1179-88. PubMed ID: 1940796
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nontoxic Shiga toxin derivatives from Escherichia coli possess adjuvant activity for the augmentation of antigen-specific immune responses via dendritic cell activation.
    Ohmura M; Yamamoto M; Tomiyama-Miyaji C; Yuki Y; Takeda Y; Kiyono H
    Infect Immun; 2005 Jul; 73(7):4088-97. PubMed ID: 15972497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel HIV IL-4R antagonist vaccine strategy can induce both high avidity CD8 T and B cell immunity with greater protective efficacy.
    Jackson RJ; Worley M; Trivedi S; Ranasinghe C
    Vaccine; 2014 Sep; 32(43):5703-14. PubMed ID: 25151041
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.